Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
171
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG:
STX-241
Sponsor
Pierre Fabre Medicament